On 15 October 2014, orphan designation (EU/3/14/1345) was granted by the European Commission to Novartis Europharm Ltd, United Kingdom, for osilodrostat for the treatment of Cushing's syndrome.
The sponsorship was transferred to Novartis Europharm Limited, Ireland in May 2018.
Osilodrostat has been authorised in the EU as Isturisa since 9 January 2020.
The sponsorship was transferred to Recordati Rare Diseases, France in March 2020.
Treatment of Cushing's syndrome
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.